01 / DUAL ACTIVE ASSAY
Full-Strength Antidepressant-Anxiolytic Ratio
Each tablet contains Escitalopram 10 mg and Clonazepam 0.5 mg with strict active assay uniformity and rapid dissolution complying with Indian Pharmacopoeia standards.
Blessme · Antidepressants & Anxiolytics
Escitalopram + Clonazepam Tablets - ESICARE-PLUS
ESICARE-PLUS is a full-strength oral neuropsychiatric formulation combining Escitalopram Oxalate IP equivalent to Escitalopram 10 mg with Clonazepam IP 0.5 mg by Blessme, Dellwich Lifescience LLP. Specifically indicated for severe major depressive disorder comorbid with debilitating panic attacks, severe agoraphobia, and intense psychic agitation, delivering immediate GABAergic tranquilization while establishing long-term serotonergic mood stabilization.
Full-Strength Dual Action
Narcotic / Schedule H
Pan-India Supply
Product SpecificationsAbout Escitalopram + Clonazepam
About Escitalopram + Clonazepam
(ESICARE-PLUS)
Detailed pharmaceutical specifications, active API monograph compliance, full-strength SSRI-GABA synergy, and 4x5x10 blister packaging details for ESICARE-PLUS.
Blessme · Antidepressant & Anxiolytic
Escitalopram + Clonazepam - ESICARE-PLUS
ESICARE-PLUS provides 10 mg Escitalopram paired with 0.5 mg Clonazepam. Formulated for patients suffering from severe depression complicated by frequent panic attacks, intense somatic anxiety, and persistent insomnia.
10 mg Escitalopram Restores Core Serotonergic Equilibrium0.5 mg Clonazepam Shuts Down Severe Panic & Somatic TerrorRapid Induction of Night-Time Sleep & Calming 4x5x10 Blister Strip Format for Tropical Protection Strict Indian Pharmacopoeia Quality Standards
- Product Brand Name
- ESICARE-PLUS
- Active Pharmaceutical Ingredients
- Escitalopram Oxalate IP eq. to Escitalopram 10 mg + Clonazepam IP 0.5 mgVerified IP
- Therapeutic Class
- Neuropsychiatric Antidepressant (SSRI) & Anxiolytic (Benzodiazepine)
- Dosage Form
- Oral Solid Compressed Tablet
- Strength Formulation
- 10 mg Escitalopram + 0.5 mg Clonazepam (Full-Strength Formulation)
- Packaging Standard
- 4x5x10 Blister Strips (200 Tablets per Box)
- Regulatory Category
- Narcotic Drug
- Marketing Division
- Blessme · Neuro & Psychiatric Products
- Manufacturing Standard
- WHO-GMP & ISO 9001:2015 Certified Clean-Room Compression
- Storage Condition
- Store below 25°C in a dry place. Protect from light and moisture.
- Country of Origin
- India
Clinical & Commercial MonographEscitalopram + Clonazepam Tablet & ESICARE-PLUS
Escitalopram + Clonazepam Tablet & ESICARE-PLUS
Complete Medical & Supply Guide
In-depth pharmacological evaluation of Escitalopram 10 mg + Clonazepam 0.5 mg tablets, marketed as ESICARE-PLUS by Blessme (Dellwich Lifescience LLP). Covers acute panic termination, major depression treatment, and pharmaceutical supply across India.
What is ESICARE-PLUS (Escitalopram 10 mg + Clonazepam 0.5 mg)?
ESICARE-PLUS is a full-strength oral neuropsychiatric formulation combining an allosteric selective serotonin reuptake inhibitor (Escitalopram 10 mg) with a high-affinity positive GABA_A modulator (Clonazepam 0.5 mg).
When psychiatrists treat patients with severe major depression comorbid with panic attacks or acute suicidal anxiety, waiting 3 to 4 weeks for SSRI monotherapy is clinically precarious. ESICARE-PLUS bridges this critical gap by delivering immediate high-potency anxiolytic coverage from day one.
Clinical Uses & Evidence-Based Indications
Approved neurological and psychiatric indications for ESICARE-PLUS include:
- Severe Major Depressive Disorder (MDD): Rapid mood stabilization with profound reduction in somatic anguish.
- Panic Disorder with Agoraphobia: Aborts recurrent panic attacks and reduces anticipatory dread.
- Refractory Generalized Anxiety Disorder: Controls severe generalized anxiety failing low-dose therapy.
- Acute Agitation & Insomnia Comorbid with Depression: Restores deep restorative nocturnal sleep.
- Severe Social Anxiety Disorder: Broad-spectrum control over severe social phobic avoidance.
Neurochemical Mechanism of Action: Serotonergic & GABAergic Synergy
Escitalopram 10 mg selectively inhibits the serotonin transporter (SERT), preventing 5-HT reuptake and steadily increasing serotonergic tone in cortical and limbic synapses over a 2 to 4-week neuroplastic adaptation period.
Simultaneously, Clonazepam 0.5 mg acts as a high-potency positive allosteric modulator on the GABAA receptor-chloride ion channel complex. By increasing chloride influx, it hyperpolarizes limbic neurons, immediately terminating acute panic attacks, motor restlessness, and severe autonomic surges from the very first dose.
Formulation Comparison: ESICARE-PLUS vs. ESICARE-LS vs. ESICARE-PLUS-H
Clinical criteria for selecting between the formulations:
- ESICARE-PLUS (10 mg + 0.5 mg): Full-strength antidepressant with higher-potency anxiolytic (0.5 mg) for severe panic crises and severe agitation.
- ESICARE-LS (10 mg + 0.25 mg): Standard therapeutic antidepressant dose (10 mg) with micro-dose anxiolytic cover (0.25 mg) for long-term maintenance with minimal daytime sedation.
- ESICARE-PLUS-H (5 mg + 0.25 mg): Starting titration dose for sensitive patients, geriatric individuals, or mild anxiety-depression overlap.
Dosage Guidelines & Administration Method
ESICARE-PLUS must be taken strictly in accordance with medical advice:
- Administration Time: Typically 1 tablet once daily, preferably at bedtime if sedation is noted.
- Swallow Whole: Take with water; do not crush or chew.
- With or Without Food: Can be taken with meals to minimize potential mild gastrointestinal upset.
- Gradual Tapering: Discontinue gradually under psychiatric guidance to avoid rebound anxiety and SSRI discontinuation symptoms.
Critical Safety Warning - Schedule H / Narcotic Controlled Substance
ESICARE-PLUS contains Clonazepam, which carries potential for dependence and habit formation with prolonged therapy. Do not consume alcohol during therapy. Contraindicated with monoamine oxidase inhibitors (MAOIs). Dispensed strictly against a valid medical prescription.
Quality & Production
Pharmaceutical Quality Assurance & Compliance
ESICARE-PLUS is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
02 / PROTECTIVE PACKAGING
High-Barrier Blister Foil
Tamper-evident, tropicalized 4x5x10 blister strips prevent moisture ingress and light-induced degradation, ensuring active ingredient stability across diverse Indian climates.
03 / PHARMACOPOEIA DOSSIERS
COA & Batch Testing Records
Every batch is backed by authenticated Certificates of Analysis (COA), disintegration profiles, assay validation data, and Material Safety Data Sheets for hospital audits.
04 / WHO-GMP COMPLIANCE
Schedule M Manufacturing
Produced in state-of-the-art accredited manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Clinical Profile & Precautions
Approved Indications & Regulatory Guidelines
Prescribing guidance, contraindications, and drug interactions for Escitalopram 10 mg + Clonazepam 0.5 mg tablets.
Prescription-Only Schedule H / Narcotic Medication Notice
ESICARE-PLUS is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Clinical Indications Profile
Approved neurological and psychiatric indications for ESICARE-PLUS:
- Severe Major Depressive Disorder: Rebalances core serotonergic neurotransmission.
- Acute Panic Disorder: Rapidly aborts panic attacks and anticipatory fear.
- Refractory GAD: Controls severe generalized anxiety and sleep disruption.
- Agoraphobia with Panic: Suppresses panic triggers in challenging environments.
Contraindications & Precautions
Key contraindications and monitoring requirements:
- MAOI Interaction: Never use concurrently with MAOIs; observe a 14-day washout period.
- QTc Interval Caution: Avoid concurrent use with medications prolonging the QT interval.
- Alcohol Prohibition: Dangerous synergism leading to severe hypotension and CNS depression.
- Gradual Discontinuation: Taper slowly under physician direction.
Manufacturing & Marketing
Dellwich Lifescience LLPBlessme · Neuro & Psychiatric Division
About Dellwich Lifescience
Trusted Neuro & Psychiatric Pharmaceutical Manufacturer in Ahmedabad, Gujarat
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including ESICARE-PLUS (Escitalopram 10 mg + Clonazepam 0.5 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Commercial PartnershipsESICARE-PLUS Supply &
ESICARE-PLUS Supply &
Pharmaceutical Distribution
Whether you are seeking ESICARE-PLUS for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Exclusive Monopoly PCD Franchise
Secure district-level monopoly marketing rights for ESICARE-PLUS and the Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Third-Party Contract Manufacturing
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Hospital & Institutional Procurement
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
Blessme · ESICARE-PLUS
Why Choose ESICARE-PLUS Tablets?
When sourcing Escitalopram Clonazepam tablets in India, ESICARE-PLUS by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
WHO-GMP Certified Purity
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and fast disintegration.
High-Barrier Blister Packaging
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and transport friction.
Pan-India Dispatch from Ahmedabad
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Monopoly PCD Franchise Rights
Exclusive district-level franchise rights for ESICARE-PLUS and the Blessme portfolio with promotional visual aids.
Comprehensive Regulatory Dossiers
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct Manufacturer Support
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Common Questions
Frequently Asked Questions about ESICARE-PLUS
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Escitalopram + Clonazepam tablets.
What is ESICARE-PLUS and what does it contain?
ESICARE-PLUS is a full-strength oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Escitalopram Oxalate IP equivalent to Escitalopram 10 mg and Clonazepam IP 0.5 mg, formulated for severe depression comorbid with acute panic crises and psychiatric agitation.
When is ESICARE-PLUS preferred over ESICARE-LS?
ESICARE-PLUS contains 0.5 mg Clonazepam (compared to 0.25 mg in ESICARE-LS). It is chosen when the patient experiences severe panic disorder, intense somatic anxiety, severe sleep disturbances, or panic with agoraphobia requiring full-strength GABAergic limbic suppression.
How does the combination in ESICARE-PLUS work?
Escitalopram 10 mg selectively inhibits the serotonin transporter (SERT), elevating synaptic 5-HT levels over 2 to 4 weeks to resolve core depressive symptoms. Concurrently, Clonazepam 0.5 mg acts immediately on GABA_A receptors, stimulating inhibitory chloride influx to provide prompt panic relief and anxiety suppression from day one.
When should ESICARE-PLUS be taken?
Psychiatrists typically advise taking ESICARE-PLUS once daily. Because 0.5 mg Clonazepam can cause sedation, taking it at bedtime is frequently recommended to promote restorative sleep while protecting against nocturnal panic awakenings.
Does ESICARE-PLUS cause daytime drowsiness?
Yes. Due to the 0.5 mg Clonazepam content, mild-to-moderate sedation, drowsiness, or lightheadedness can occur, particularly during initial days of therapy. Patients should avoid driving, operating heavy machinery, or hazardous tasks until individual tolerance is established.
Can ESICARE-PLUS be stopped suddenly?
No. Abrupt stoppage can precipitate severe withdrawal symptoms (sensory disturbances, dizziness, rebound anxiety, insomnia) due to simultaneous cessation of the SSRI and benzodiazepine. Gradual dose tapering under psychiatric direction is mandatory.
Can I drink alcohol while taking ESICARE-PLUS?
Alcohol is strictly prohibited. Combining alcohol with Escitalopram and Clonazepam can cause dangerous central nervous system depression, extreme sedation, respiratory suppression, and memory blackouts.
Is ESICARE-PLUS habit-forming?
The Clonazepam component belongs to the benzodiazepine class and carries potential for dependence and tolerance when taken continuously over long periods. Clinicians typically evaluate the patient after 4 to 8 weeks to determine tapering strategies for the benzodiazepine.
What are common side effects of ESICARE-PLUS?
Common side effects include drowsiness, fatigue, dry mouth, mild nausea, changes in appetite, or mild dizziness. Most side effects subside as the body adapts over the first two weeks of treatment.
Can pregnant women take ESICARE-PLUS?
Use during pregnancy is contraindicated unless specifically evaluated by a medical specialist, as both Escitalopram and Clonazepam can pose risks to the developing fetus.
How is ESICARE-PLUS packaged?
ESICARE-PLUS is supplied in premium 4x5x10 blister strips (200 tablets per box) manufactured with high-barrier foil to guarantee extended shelf life across all Indian climate conditions.
How can distributors apply for PCD franchise monopoly for ESICARE-PLUS?
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Does Dellwich Lifescience offer third-party manufacturing for ESICARE-PLUS?
Yes. Dellwich Lifescience provides turnkey contract manufacturing for Escitalopram + Clonazepam combinations with GMP certification, customized branding, and on-time shipment dispatch.
Where is Dellwich Lifescience headquartered?
Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with rapid logistics connections across all Indian states.
Direct Pharmaceutical Enquiry
Need Verified Information or Bulk Supply of ESICARE-PLUS?
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Direct Manufacturer Pricing & Transparent MOQ
Exclusive PCD Monopoly Rights for Designated Districts
Fast Dispatch from Ahmedabad with GST Invoicing
Comprehensive Marketing, Visual Aids & Promotional Inputs
Quick Assistance & Orders
Enquire About ESICARE-PLUS
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Escitalopram 10 mg + Clonazepam 0.5 mg Tablets.